aTyr Pharma Inc.'s management held an investor call on September 15, 2025, where they announced that the EFZO-FIT study for their drug Efzofitimod did not meet its primary endpoint regarding the change from baseline in mean daily OSC dose at week 48. The company also stated that their next step would be to engage with the FDA to determine a path forward following the disappointing topline results. The full podcast describing the nature of the class action lawsuit related to these events is available at https://www.podbean.com/player-v2/?i=mj5ct-19ad352-pb&from=pb6admin&pbad=0&share=1&download=1&rtl=0&fonts=Arial&skin=1&font-color=auto&logo_link=episode_page&btn-skin=7.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097270) on November 05, 2025, and is solely responsible for the information contained therein.